Navigation Links
New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

BALTIMORE, Jan. 27 /PRNewswire/ -- Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for Thrombosis Research based at Sinai Hospital of Baltimore, indicate that platelet aggregation or "stickiness" may be the single largest factor in determining the likelihood of developing serious complications, including heart attack, in patients treated with coronary artery stents.

"We currently measure the cholesterol level in everyone with vascular disease, yet the pivotal event that kills the patient - platelet aggregation isn't being assessed in any way," said Dr. Gurbel.

Dr. Gurbel's findings may explain why someone with no cardiac history could die suddenly of a massive heart attack, while an individual with high blood pressure, high cholesterol and plaque-filled arteries may never have a cardiac event because they had low platelet aggregation.

Along with his team at Sinai, Dr. Gurbel demonstrated that patients with platelets most prone to aggregate had the highest prevalence of complications, including heart attack, after coronary artery stenting.

Their work is helping to revolutionize the testing and treatment of patients with coronary artery disease, offering further evidence that a more personalized approach to anti-platelet therapy needs to be established.

Dr. Gurbel was one of the first researchers in the world to discover that up to 30% of patients taking clopidogrel, a drug designed to decrease platelet aggregation, do not respond to treatment.

"Of the millions of cardiac patients treated with clopidogrel, a significant percentage are non-responsive and remain at high risk for a major cardiac event," said Dr. Gurbel. "The platelet aggregation of each patient needs to be precisely measured to determine how well the drug is working. The blind administration of anti-platelet drugs without confirming a good response, in our opinion, will soon be reaching an end."

Click here for a recent story on Dr. Gurbel's research -

About Sinai Hospital of Baltimore

Sinai Hospital of Baltimore is part of LifeBridge Health, a regional health organization that also includes Northwest Hospital, Levindale Hebrew Geriatric Center and Hospital, Jewish Convalescent & Nursing Home, and related subsidiaries and affiliates.

SOURCE Sinai Hospital of Baltimore
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Why Wait for an Anti-Aging Drug? Researchers Interviewed on CBS-TVs 60 MINUTES Discover Longevinex(R) Nutriceutical Matrix Activates 9-Fold More Longevity Genes than Plain Resveratrol
2. Phidea Srl and Marvin Research Srl Announce Completion of Merger
3. Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
4. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
5. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
6. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
7. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
8. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
9. 2008 Human Research Protection Award Recipients Announced
10. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
11. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... According to an article published November 13th on, much ... revolved around the fact that proper dental care, both at-home and in the dental ... periodontal disease (more commonly referred to as gum disease) and diabetes. According to Dr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was ... inventor from Hillside, N.J. "Many people catch diseases simply from sitting on such ... always be protected from germs." , He developed the patent-pending QUDRATECS to eliminate ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South ... 750,000. The digital component is distributed nationally, through a vast social media strategy ...
Breaking Medicine News(10 mins):